We report the case of a 56 year-old Hispanic male with a 10-year history of type 2 diabetes who presented with abrupt onset of hyperglycemia resistant to escalating doses of intravenous insulin infusion (>2500 units daily). He was diagnosed with antibody-mediated insulin resistance given the presence of hyperglycemia despite receiving >200 units insulin/day, a lack of identifiable precipitants for diabetic ketoacidosis or hyperosmolar hyperglycemic state, and elevated insulin antibodies. He underwent pre-immunomodulatory therapy screening for infections, rheumatologic disorders, and malignancy, which uncovered a new diagnosis of latent tuberculosis. While concurrently being treated for latent tuberculosis, he successfully responded to immunomodulatory therapy with rituximab, dexamethasone, and cyclophosphamide. Insulin was discontinued completely, and he maintained appropriate glycemic control on oral diabetic agents (metformin and pioglitazone). This case supports the use of immunomodulatory therapy for the treatment of antibody-mediated insulin resistance and highlights the importance of pre-immunomodulatory therapy screening to uncover occult infection or identify underlying neoplastic/rheumatologic disease prior to immunosuppression.
Background
: Antibody-mediated extreme insulin resistance is characterized by hyperglycemia despite the use of >200 units of insulin/day and is often divided into two subtypes, insulin receptor antibody-mediated (Type B insulin resistance) and insulin antibody-mediated insulin resistance. The National Institutes of Health (NIH) published an immunomodulatory protocol for the treatment of Type B insulin resistance (1). However, there is scarce data on immunomodulatory therapy use for insulin antibody-mediated insulin resistance, and little has been documented to guide pretreatment screening.
Clinical Case
: We report the case of a 56 year-old Hispanic male with a 10-year history of well-controlled type 2 diabetes, who presented with abrupt onset hyperglycemia/diabetic ketoacidosis resistant to escalating doses of intravenous insulin infusion (>2500 units daily). He was diagnosed with antibody-mediated insulin resistance due to hyperglycemia requiring very high doses of insulin, lack of identifiable precipitants for diabetic ketoacidosis or hyperosmolar hyperglycemic state, and elevated insulin antibody levels. He underwent pre-immunomodulatory therapy screening for infections, rheumatologic disorders, and malignancy, which uncovered a new diagnosis of latent tuberculosis. He was started on treatment for latent tuberculosis, and began immunomodulatory therapy using the protocol developed by the NIH with rituximab, dexamethasone, and cyclophosphamide. One month after the second therapy cycle, insulin was no longer required for glycemic control, and he maintained appropriate glycemic control on oral diabetic agents alone (metformin and pioglitazone).
Conclusion
: This case validates the use of immunomodulatory therapy for the treatment of insulin antibody-mediated insulin resistance. It also highlights the importance of pre-immunomodulatory therapy screening to uncover occult infection prior to immunosuppression, and to investigate for possible causal neoplastic or rheumatologic disease. We propose an algorithm for pre-immunomodulatory screening prior to therapy in patients with antibody-mediated insulin resistance.
Reference:
(1) Malek R, Chong AY, Lupsa BC, et al. Treatment of Type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.
The Journal of Clinical Endocrinology & Metabolism
. 2010;95(8):3641-3647.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.